drugset / Trial / NCT02882191

Evaluation of the Efficacy and Safety of LevoCept

NCT02882191

Phase 2 Completed 279 enrolled Sebela Women's Health Inc. Synteract, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the effectiveness, device placement, safety, and tolerability of LevoCept to support commencing a Phase III Clinical Study

Timeline

Start
2016-11
Primary completion
2018-07-17
Completion
2020-11-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Levonorgestrel Small molecule Other

Indications

No indication recorded.